Efficacy of a formulation of sarolaner/moxidectin/pyrantel (Simparica Trio®) for the prevention of Thelazia callipaeda canine eyeworm infection

Marcos Antonio Bezerra-Santos1, Jairo Alfonso Mendoza-Roldan1, Giovanni Sgroi1, Riccardo Paolo Lia1, Giulia Venegoni2, Fabrizio Solari Basano3, Roose Nele3, Sean P. Mahabir4, Stasia Borowski3, Thomas Geurden3 and Domenico Otranto1,5*

Abstract

Background: For a long time known as the oriental eyeworm, Thelazia callipaeda is a zoonotic nematode that infects the eyes of a wide range of vertebrate hosts including dogs, cats, wildlife carnivores, lagomorphs, and humans. The high occurrence of this infection in Europe and the first cases in the United States have increased scientific interest in the parasite, as it also represents a risk for people living in endemic areas. Therefore, treatment and prevention of thelaziosis in canine population are advocated to reduce the risk of human infection as well. Here, we assessed the efficacy of a formulation containing sarolaner/moxidectin/pyrantel (Simparica Trio®) administered orally at monthly intervals, for the prevention of establishment of infection with T. callipaeda in naturally infected dogs. In this formulation, moxidectin is expected to have efficacy against eyeworms, whereas sarolaner and pyrantel are not.

Methods: The study was conducted in eyeworm endemic areas of Italy and France, where dogs (n = 125) were assigned into two groups consisting of a negative control group (G1; n = 62), in which animals were treated monthly with a control product (sarolaner; Simparica®), and a treatment group (G2; n = 63) in which animals were treated monthly with Simparica Trio (sarolaner/moxidectin/pyrantel) from day 0 to day 150. In total, nine animals were withdrawn from the study (two animals became positive at day 30, and seven for reasons unrelated to eyeworm infection), resulting in 116 animals (n = 58 for G1; n = 58 for G2).

Results: In G1, 16 out of 58 animals (27.6%) were observed with eyeworms during the study, and none of the animals from G2 were ever observed with eyeworms, resulting in 100% efficacy (P < 0.0001) in the prevention of establishment of T. callipaeda infection. Adult nematodes and fourth-instar (L4)-stage larvae were recovered from the eyes of positive animals, counted, and morphologically identified as T. callipaeda. In addition, specimens from Italy were molecularly confirmed as belonging to the haplotype 1 (i.e., the only one circulating in Europe so far).

Conclusions: Data presented herein demonstrated 100% efficacy of Simparica Trio for the prevention of T. callipaeda eyeworm infection in dogs from highly endemic areas of France and Italy. The use of this formulation is advantageous, as it is a licensed product in Europe with a wide efficacy spectrum against other nematodes, multiple tick species, and...
Background

*Thelazia callipaeda* is a zoonotic nematode widely distributed in Asia and Europe [1]. This parasite, once known as the oriental eyeworm, infects a wide range of vertebrate hosts including domestic animals (e.g., dogs and cats), wild fauna (e.g., beech martens, bears, foxes, jackals, wolves), and humans [2, 3], causing ocular infections characterized by different degrees of conjunctivitis, follicular hypertrophy of the conjunctiva, discomfort, epiphora, itchiness, congestion, swelling, hypersensitivity to light, and keratitis [4]. The vectors of this nematode are drosophilid fruit flies of the species *Phortica variegata* in Europe, and *Phortica okadai* in Asia [5]. However, a third species, *Phortica oldenbergi*, has been demonstrated as a potential vector of *T. callipaeda* under experimental conditions [6]. In Europe, since the first report of this nematode in Italy [7], several other cases have been reported in other countries in different domestic and wild animal species, indicating a wide vertebrate host range for *T. callipaeda*, and supporting wild carnivores as important players on the spreading of this eyeworm in endemic areas, as well as in remote environments [1–3, 8].

The high prevalence of *T. callipaeda* in dogs from specific geographical areas in Italy (up to 41.76% [9]), Spain (up to 61.3% [4]), Serbia (up to 35.52% [10]), and France (no prevalence data, but a high number of reported cases [11]) suggests that stable endemic foci of the infection occur [12]. Conversely, lower prevalence in Switzerland (i.e., 5.3% [13]) and Portugal (i.e., 3.8% [14]) may indicate the emergence of this parasite in previously non-endemic countries [12]. The high occurrence of this infection in dogs is also risky for people living close to them, as the vector, *P. variegata*, feeds on lachrymal secretions of several vertebrate hosts, including dogs and humans [15]. Therefore, treatment and prevention of this infection in dogs from endemic areas is advocated to reduce the risk to human health as well.

Different macrocyclic lactone formulations have been tested against *T. callipaeda* infection in dogs (e.g., moxidectin 2.5% and imidacloprid 10%, milbemycin oxime/praziquantel, milbemycin oxime/afloxolane) demonstrating efficacy ranging from 90 to 100% against this eyeworm infection [16–19]. In addition, the prevention of the eyeworm with either moxidectin and milbemycin oxime has been demonstrated in dogs from Italy, France, and Spain [19–21]. In order to widen the spectrum of preventive treatment options available for eyeworm infection and to provide a prophylaxis tool for new cases of infection in endemic areas, this study assessed the efficacy of Simparica Trio® administered at the minimum doses of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, and 5 mg/kg pyrantel at monthly intervals, for the prevention of establishment of infection with *T. callipaeda* in dogs from highly endemic areas in Europe.

Methods

Study design

The study was conducted in the Basilicata region in southern Italy and in three veterinary clinics in the Nouvelle-Aquitaine region in France (Fig. 1). Both study areas are endemic for *T. callipaeda* eyeworms, with previously reported cases of thelaziosis in dogs [9, 11, 22], as well as high abundance of *P. variegata* vectors [23]. The study was conducted under the principles of Good Clinical Practice (GCP), as a controlled, blinded, and randomized multi-center field study. An informed consent form was signed by the dog owners before inclusion in the study.

During a pre-screening visit (days −28 to −14), animals were clinically evaluated for suitability for inclusion in the study. All animals were examined for the presence of adult *T. callipaeda* worms in both eyes, including a thorough examination underneath the third eyelid and conjunctival pouch flushing with 5 ml of saline solution (0.9%), which was preserved in sterile tubes. After removal of *T. callipaeda* adult worms from the tubes, further centrifugation for 5 min at 700×g was performed, the supernatant was aspirated, and the sediment (1 ml solution) was analyzed under an optical microscope at ×40 magnification for the detection of nematode larvae. The collected nematodes (Fig. 2) were morphologically identified according to published keys [24, 25]. Following the pre-screening visit, all animals received a treatment with Milbemax®.

On day 0, animals were again physically evaluated, and ocular examination was performed in each dog. Animals that scored negative for *T. callipaeda* eyeworm and met all the criteria to be included in the study (i.e., ≥8 weeks of age, ≥2 kg, not pregnant or lactating, and not intended for breeding during the study) were enrolled and randomly assigned to treatment groups (G1: control product consisting of sarolaner [Simparica®]; and G2: investigated product consisting of sarolaner/moxidectin/pyrantel [Simparica Trio]), with both products presented as a flavored hard chewable tablet administrated orally.

Keywords: *Thelazia callipaeda*, Prevention, Dogs, Moxidectin, Simparica Trio, Zoonosis
Follow-up treatments were provided on days 30 (±3), 60 (±3), 90 (±3), 120 (±3), and 150 (±3) for all animals that remained negative for eyeworm infection, as diagnosed during ophthalmological assessment. If an animal was found positive for the presence of *T. callipaeda* adults on any of these follow-up treatment days, it was excluded from the study and received a commercial spot-on treatment with moxidectin/imidacloprid (Advocate®). All products were administered according to the European Union (EU) label instructions, and doses were selected according to the animal’s weight. At study completion on day 180 (±3), animals received a general physical examination and ophthalmological assessment. Throughout the study period, all animals were observed daily by the owners for any health abnormality, and in the case of any adverse event, the investigator was contacted to examine the dog, evaluate whether the animal could continue in the study, and document diagnosis and concomitant treatment.

**Nematode identification**

Nematodes collected from Italy and France were identified according to morphological keys [24, 25], and specimens from Italy were also identified by molecular characterization of partial (689 base pairs) mitochondrial cytochrome *c* oxidase subunit 1 (*cox1*) gene. Briefly, genomic DNA of worms collected from the eyes of positive dogs was extracted using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). Conventional polymerase chain reaction (PCR) was performed using the primers NTF (5’-TGATTGGTGGTTTGGTA-3’) and NTR
(5′-ATAAGTACGAGTATCAATATC-3′), and amplicons were purified and sequenced in both directions using BigDye Terminator v.3.1 chemistry in a 3130 Genetic Analyzer (Applied Biosystems, Waltham, MA, USA) in an automated sequencer (ABI Prism 377). Sequences were analyzed with MEGA7 software and compared with those available in the GenBank database through the BLAST search tool.

**Statistical analysis**
A minimum sample size of 52 dogs per group was calculated based on the number of animals sufficient to detect a difference between infection rates for control product (G1) and treated (G2) animals with at least 80% power at the two-sided 5% significance level, assuming a maximum infection rate of 2% for treated animals and a minimum infection rate of 20% for control animals. A dog was considered positive as soon as an adult eyeworm was observed anytime during the study period. If adult eyeworms were observed on day 30, the dog was excluded from efficacy analyses, as the animal was assumed to have been infected before day 0. The proportion of eyeworm-free dogs was summarized in two-way frequency tables (eyeworm-free x treatment). The treatment was considered effective if the proportion of ever eyeworm-positive dogs in the treated group was significantly lower than in the control group and if it was at least 90% efficacious, using the following formula:

\[
\text{% Efficacy} = 100 \times \left( \frac{p_C - p_T}{p_C} \right),
\]

where \( p_C \) is the proportion of animals infected for the control (G1) and \( p_T \) is the proportion of animals infected for the treated group (G2).

Fisher’s exact test was used to compare treatment groups for the presence of eyeworm during the study (yes/no). The test was conducted at the two-sided 0.05 significance level. Nematode counts were summarized by treatment group and stage (individual levels and overall) with descriptive statistics (mean, median, standard deviation, minimum and maximum).

**Results**
A total of 125 dogs (\( n = 70 \) from Italy; \( n = 55 \) from France) were included in the study on day 0 (Table 1); however, nine animals were withdrawn during the study (two that became positive at day 30, and seven due to reasons unrelated to eyeworm infection), leaving 116 animals (\( n = 58 \) in G1; 58 in G2).

In the control group (G1), 16 out of 58 animals (27.6%) were observed with eyeworms during the study. In the treated animals (G2), no eyeworm infections were detected, indicating 100% efficacy (\( P < 0.0001 \)) in the prevention of establishment of *T. callipaeda* infection in dogs for at least 28 days after treatment with Simparica Trio (Table 2).

Adult nematodes and L4-stage larvae were recovered from the eyes of positive animals, counted, and morphologically identified as *T. callipaeda* (Table 3), which were molecularly confirmed as belonging to haplotype 1 with 100% nucleotide identity with other *T. callipaeda* sequences (AM042549.1; OK662943.1) available in GenBank.

Moderate or mild clinical signs were observed in *T. callipaeda*-positive animals from G1 at follow-up visits and consisted of conjunctivitis and ocular discharge (Additional file 1: Table S1).

**Discussion**
The use of a monthly treatment with Simparica Trio resulted in 100% efficacy in preventing ocular thelaziosis by *T. callipaeda* in dogs from two different endemic areas in Europe, as such providing a reliable control strategy against this nematode in dogs. The prevention of thelaziosis in dogs using Simparica Trio was assessed through treatment followed by ocular examination every month over a 6-month period (May–November), which represents the period of the year when high numbers of

### Table 1 Breed, sex, hair type, housing conditions and the number of dogs included in the study and receiving concomitant medication at enrolment

| Characteristics               | G1 (n = 62) | G2 (n = 63) |
|-------------------------------|------------|------------|
|                               | n | %       | n | %       |
| Breed                         |  |          |  |          |
| Purebred                      | 51 | 82.3 | 51 | 81.0 |
| Non-purebred                  | 11 | 17.7 | 12 | 19.0 |
| Animal spends time            |  |          |  |          |
| Indoors and outdoors          | 19 | 30.6 | 20 | 31.7 |
| Mostly outdoors               | 43 | 69.4 | 43 | 68.3 |
| Sex                           |  |          |  |          |
| Male                          | 31 | 50.0 | 41 | 65.1 |
| Female                        | 31 | 50.0 | 22 | 34.9 |
| Hair type                     |  |          |  |          |
| Long                          | 9 | 14.5 | 11 | 17.5 |
| Medium                        | 20 | 32.3 | 14 | 22.2 |
| Short                         | 33 | 53.2 | 38 | 60.3 |
| Therapeutic/prophylactic medication |  |        |  |        |
| On medication                 | 2 | 3.2 | 4 | 6.3 |
| Not on medication             | 60 | 96.8 | 59 | 93.7 |

G1: control group consisting of sarolaner (Simparica®). G2: investigated veterinary product consisting of sarolaner/moxidectin/pyrantel (Simparica Trio®) n: number of dogs, %: percentage of all dogs

Additional file 1: Table S1.
infections are registered [9] due to the occurrence of *P. variegata* in the environment as well [5].

The high efficacy of Simparica Trio against *T. callipaeda* reported herein is due to the presence of moxidectin, which acts against diverse species of parasitic nematodes (e.g., *Toxocara canis, Ancylostoma caninum*) [26]. The combination with pyrantel complements the anthelmintic efficacy spectrum of action (against *Toxascaris leonina* and *Uncinaria stenocephala*), being also efficacious against *Dirofilaria immitis* [27] and *Angiostrongylus vasorum* [28]. In addition, the wide spectrum of this oral formulation against other nematodes (i.e., *T. canis, A. caninum, T. leonina, U. stenocephala, D. immitis,* and *A. vasorum*), as well as against ticks and fleas, is an advantage as it protects dogs against a plethora of endo- and ectoparasites of veterinary and public health importance.

In animals from the control group (G1) that scored positive for eyeworms, the most common clinical signs observed were mild conjunctivitis and ocular discharge, which are among the clinical presentations of ocular thelaziosis by *T. callipaeda*, not only in dogs but also in other animal species [4]. The absence of other symptoms associated with this eyeworm infection in the positive

### Table 2

| Treatment group | Eyeworms |  |  |  |  |  |  |  |  |  |  |
|-----------------|----------|----------|----------|----------|----------|
|                 | Negative | Positive | Negative | Positive | Negative | Positive |
|                 | n (%)    | n (%)    | n (%)    | n (%)    | n (%)    | n (%)    |
| G1 (Simparica)  | 42 (72.4%) | 16 (27.6%) | 58 (100%) | 58 (100%) |
| G2 (Simparica Trio) | 58 (100%) | 0 (0%) | 58 (100%) | 58 (100%) |

*n*: number of dogs, %: percentage of all dogs

### Table 3

| Treatment group | Animal | L1 | L3 | L4 | L5 | Adults | Total |
|-----------------|-------|----|----|----|----|--------|-------|
| G1 (Simparica)  | 1     | –  | –  | –  | –  | 3      | 3     |
|                 | 2     | –  | –  | –  | –  | 4      | 4     |
|                 | 3     | –  | –  | –  | –  | 2      | 2     |
|                 | 4     | –  | –  | –  | –  | 1      | 1     |
|                 | 5a    | –  | –  | –  | –  | –      | –     |
|                 | 6     | –  | –  | –  | –  | 4      | 4     |
|                 | 7     | –  | –  | –  | –  | 7      | 7     |
|                 | 8     | –  | –  | –  | –  | 2      | 2     |
|                 | 9     | –  | –  | –  | –  | 3      | 3     |
|                 | 10    | –  | 2  | –  | –  | 1      | 3     |
|                 | 11    | –  | –  | –  | –  | 5      | 5     |
|                 | 12a   | –  | –  | –  | –  | –      | –     |
|                 | 13    | –  | 3  | –  | –  | 3      | 3     |
|                 | 14    | –  | –  | –  | –  | 4      | 4     |
|                 | 15    | –  | –  | –  | –  | 2      | 2     |
|                 | 16    | –  | –  | –  | –  | 2      | 2     |

*a* Animals in which nematodes were observed but not recovered

Studies on the efficacy of diverse chemical compounds against *T. callipaeda* infection have been performed in dogs [16–20, 31] and cats [17, 32] using several formulations, including moxidectin 2.5% and imidacloprid 10% [18], milbemycin oxime/praziquantel [17], milbemycin oxime/afloxaner [19], and fipronil/(S)-methoprene/eprinomectin/praziquantel [32]. Here, the oral formulation (minimal commercial dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, and 5 mg/kg pyrantel) has been proved 100% efficacious in preventing eyeworm infections in dogs, adding a new option available in the market for the prevention of *T. callipaeda* eyeworm infections.
animals evaluated herein could be related to the low parasitic burden (i.e., minimum one and maximum seven adult eyeworms in one or both eyes). Indeed, it is suggested that the number of *T. callipaeda* adults within the eyes is correlated with the severity of the infection [1, 4]. The areas selected for this study provided suitable spots for the realization of the trials, as in these sites, *T. callipaeda* infections in dogs and wild canids such as wolves and foxes have been reported in several studies [9, 19, 22, 24, 33, 34]. Selecting study areas already known to be endemic for this parasite is essential for conducting these kinds of studies aiming to test the efficacy of endo- and ectoparasicicides for the prevention of infections by vector-borne diseases [35]. As *T. callipaeda* is highly endemic in several European countries, the evaluation of products already licensed for other parasitic agents is also an advantage that facilitates their use against thelaziosis in dogs. For example, Simparica Trio is currently licensed in Europe for nematodes, ticks, and fleas [26]. In addition, the same product is licensed for the treatment of parasitic nematode and ectoparasite infestation in dogs in the USA, where the first autochthonous case of *T. callipaeda* in a dog was published in 2021 [36]. This advantage makes the product a good candidate and increases the options for products highly efficacious in treating and preventing infection by this eyeworm in dogs.

The prevention of *T. callipaeda* infecting dogs in highly endemic areas should be considered a priority for public health, as this parasite is well known to infect humans as well, with several reports published worldwide [37–43]. Therefore, since dogs are considered domestic reservoirs and main vertebrate hosts of this nematode [1], preventing the development of infection in these animals could also be a prophylaxis measure for zoonotic infection in humans inhabiting endemic areas [15].

**Conclusion**

Data presented herein demonstrate 100% efficacy of Simparica Trio for the prevention of *T. callipaeda* eyeworm infection in dogs from highly endemic areas of France and Italy. Considering that this formulation is currently licensed in Europe (with several countries endemic for *T. callipaeda*) and the USA (first autochthonous case of *T. callipaeda* in a dog detected in 2021) for the treatment of a wide range of endo- and ectoparasites, its use is advantageous for protecting dogs against these parasitic agents, which may indirectly reduce the risk of human infection.

**Abbreviations**

GCP: Good clinical practice; G: Group; EU: European Union; DNA: Deoxyribonucleic acid.

---

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13071-022-05501-6.

**Additional file1: Table S1.** Severity of the observed clinical signs for the eyeworm-positive dogs (only G1) by visit day.

**Acknowledgements**

Authors thank Giada Annoscia (University of Bari) for the support on the molecular analysis.

**Author contributions**

MAR: Investigation, methodology, formal analysis, data curation, writing—original draft, writing—review and editing. JAMR: Investigation, methodology, writing—review and editing. GS: Investigation, methodology, writing—review and editing. RPL: Investigation, methodology, writing—review and editing. PH: Investigation, project administration, validation, writing—review and editing. FSB: Investigation, project administration, validation, writing—review and editing. DO: Conceptualization, funding acquisition, investigation, methodology, project administration, data curation, validation, writing—review and editing. All authors read and approved the final manuscript.

**Funding**

This study was supported by Zoetis.

**Availability of data and materials**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Declarations**

**Ethics approval and consent to participate**

All procedures performed in this work were approved by the Ethical Committee for Animal Experimentation of the University of Bari (Protocol number: 06/2021).

**Consent for publication**

Not applicable.

**Competing interests**

Authors Stasia Borowski, Nele Roose, Sean Mahabir and Thomas Geurden were employees of Zoetis at the time of the study. The other authors declare no competing interests.

**Author details**

1. Department of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy.
2. Arcoblu s.r.l, Milan, Italy.
3. Zoetis, Mercuriusstraat 20, 1930 Zaventem, Belgium.
4. Zoetis, Portage Street 333, Kalamazoo, MI 49007, USA.
5. Department of Pathobiology, Faculty of Veterinary Science, Bu-Ali Sina University, Hamedan, Iran.

**Received:** 28 July 2022  **Accepted:** 13 September 2022  **Published online:** 16 October 2022

**References**

1. Otranto D, Mendoza-Roldan JA, Dantas-Torres F. Thelazia callipaeda. Trends Parasitol. 2021. https://doi.org/10.1016/j.pt.2020.04.013.
2. da’Vale B, Lopes AP, da Conceição Fontes M, Silvestre M, Cardoso L, Coelho AC. Thelaziosis due to *Thelazia callipaeda* in Europe in the 21st century—a review. Vet Parasitol. 2019. https://doi.org/10.1016/j.vetpar.2019.108957.
3. Papadopoulos E, Komenou A, Karamanlidis AA, Bezerra-Santos MA, Otranto D. Zoonotic Thelazia callipaeda eyeworm in brown bears (Ursus arctos): a new host record in Europe. Transbound Emerg Dis. 2021. https://doi.org/10.1111/tbed.14414.

4. Marino V, Gámez R, Montoya A, Mascarún C, Hernández M, Barrera JP, et al. Spain as a dispersion model for Thelazia callipaeda eyeworm in dogs in Europe. Prev Vet Med. 2020. https://doi.org/10.1016/j.prevetmed.2020.104883.

5. Otranto D, Cantacessi C, Testini G, Lia RP. Phorotica variegata as an intermediate host of Thelazia callipaeda under natural conditions: evidence for pathogen transmission by a male arthropod vector. Int J Parasitol. 2006. https://doi.org/10.1016/j.ijpara.2006.06.006.

6. Bezerra-Santos MA, Bernardini I, Lia RP, Mendoza-Roldán JA, Beugnet F, Pombi M, et al. Phorotica oldeenbergi (Diptera: Drosophilidae): a new potential vector of the zoonotic Thelazia callipaeda eyeworm. Acta Trop. 2022. https://doi.org/10.1016/j.actatropica.2022.105665.

7. Rossi L, Bertaglia PP. Presence of Thelazia callipaeda Railliet & Henry, 1910, in Piedmont Italy. Parasitologia. 1989;31:167–72.

8. Bezerra-Santos MA, Moroni B, Mendoza-Roldán JA, Perrucci S, Cavicchio P, Cordón R, et al. Wild carnivores and Thelazia callipaeda zoonotic eyeworms: a focus on wolves. Int J Parasitol Wildl. 2022. https://doi.org/10.1016/j.ijpara.2022.03.005.

9. Otranto D, Ferroglio E, Lia RP, Traversa D, Rossi L. Current status and epidemiological observation of Thelazia callipaeda (Spirurida, Thelaziidae) in dogs, cats and foxes in Italy: a “coincidence” or a parasitic disease of the Old Continent? Vet Parasitol. 2003. https://doi.org/10.1016/j.vetpar.2003.07.022.

10. Hadžić-Milić M, Ilčić T, Stepanović P, Đorđević J, Dimitrijević S. Serbia: another endemic region for canine ocular thelaziasis. Med Weter. 2016. https://doi.org/10.21521/mw.5561.

11. Ruytoor P, Déan E, Pennant O, Dorchies P, Chermette R, Otranto D, et al. Emergence of canine ocular thelaziosis caused by Thelazia callipaeda in Europe 2001–2020. Parasite. 2020. https://doi.org/10.1051/pst/20017.

12. Kryda K, Mahabir SP, Chapin S, Holzmer SJ, Bowersock L, Everett WR, et al. Systematic review on infection and disease caused by Thelazia callipaeda (Spirurida, Thelaziidae) eyeworms: a focus on wolves. Int J Parasitol Wildl. 2022. https://doi.org/10.1016/j.ijpara.2022.03.005.

13. Nourfard O, Jafari A, Shahrokhi A. Efficacy of orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the prevention of experimental Angiostrongylus vasorum infection in dogs. Parasite Vectors. 2020. https://doi.org/10.1186/s13071-020-04983-0.

14. Zanet S, Morelli S, Di Cesare A, Bò S, Traversa D, Lebon W, et al. Efficacy of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea and tick infestations on dogs presented as veterinary patients in Europe. Parasite Vectors. 2020. https://doi.org/10.1186/s13071-020-3948-z.

15. Becskei C, Fias D, Mahabir SP, Bowersock L, Everett WR, et al. Efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced infestations of five common tick species infesting dogs in the USA. Parasite Vectors. 2020. https://doi.org/10.1186/s13071-020-3945-2.

16. Becskei C, Fias D, Mahabir SP. Efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against infection in naturally infected dogs. Vet Rec. 2004;154:143–5. https://doi.org/10.1136/0090-3558.43.3.508.

17. Zanet S, Morelli S, Di Cesare A, Bò S, Traversa D, Lebon W, et al. Efficacy of fipronil/(S)-methoprene/eprinomectin/praziquantel (Broadline®) in reducing the risk of vector-borne pathogen transmission in dogs and cats. Vet Parasitol. 2021. https://doi.org/10.1016/j.vetpar.2021.109369.

18. Zanet S, Morelli S, Di Cesare A, Bò S, Traversa D, Lebon W, et al. Efficacy of fipronil/(S)-methoprene/eprinomectin/praziquantel (Broadline®) against Angiostrongylus vasorum infection in dogs. Parasite Vectors. 2021;4:1477. https://doi.org/10.1186/s13071-021-05083-0.

19. Otranto D, Cantacessi C, Mallla E, Lia RP. First report of Thelazia callipaeda (Spirurida, Thelaziidae) in wolves in Italy. J Wildl Dis. 2007;43:508–11. https://doi.org/10.7589/0090-3558-43.3.508.

20. Otranto D, Deplazes P. Zoonotic nematodes of wild carnivores. Int J Parasitol Wildl. 2019;8:370–83. https://doi.org/10.1016/j.ijpara.2018.10.011.

21. Otranto D, Dantas-Torres F, Foureir JJ, Lorosso V, Varlond M, Gracioni L, et al. World Association for the Advancement of Veterinary Parastology (W.A.A.V.P.) guidelines for studies evaluating the efficacy of parasites in reducing the risk of vector-borne pathogen transmission in dogs and cats. Vet Parasitol. 2021. https://doi.org/10.1016/j.vetpar.2021.109369.

22. Schwartz AB, Lejeune M, Verocai GG, Young R, Schwartz PH. Autochthonous Thelazia callipaeda infection in New York, USA. 2020. Emerg Infect Dis;27:1923–6. https://doi.org/10.3201/eid2707.201901.

23. Otranto D, Dutto M. Human thelaziasis, Europe. Emerg Infect Dis. 2008;14:647–9. https://doi.org/10.3201/eid1407.071205.

24. Fuentes I, Montes I, Saugem JM, Latrofa S, Gárate T, Otranto D. Thelaziosis in humans, a zoonotic infection, Spain, 2011. Emerg Infect Dis. 2012;18:2073–5. https://doi.org/10.3201/eid1812.120472.

25. Tašić-Otelević S, Gabrielli S, Trenčiš-Kožinovčić M, Petrović A, Gajić B, Colella V, et al. Eyeworm infections in dogs and in a human patient in...
serbia: a one health approach is needed. Comp Immunol Microbiol Infect Dis. 2016;45:20–2. https://doi.org/10.1016/j.cimid.2016.01.003.

40. Dolf S, Kehrmann J, Eiermann P, Dalbah S, Tappe D, Rating P. Case report: *Thelazia callipaeda* eye infection: the first human case in Germany. Am J Trop Med Hyg. 2020;102:350–1. https://doi.org/10.4269/ajtmh.19-0483.

41. Wei X, Liu B, Li Y, Wang K, Gao L, Yang Y. A human corneal ulcer caused by *Thelazia callipaeda* in Southwest China: case report. Parasitol Res. 2020;119:3531–4. https://doi.org/10.1007/s00436-020-06850-w.

42. Li Y, Liu J, Tian Q, Guo D, Liu D, Ma X, et al. *Thelazia callipaeda* infection during phacoemulsification cataract surgery: a case report. BMC Ophthalmol. 2021. https://doi.org/10.1186/s12886-021-02117-9.

43. Morgado ACT, Do Vale B, Ribeiro P, Coutinho T, Santos-Silva S, De Sousa Moreira A, et al. First report of human *Thelazia callipaeda* infection in Portugal. Acta Trop. 2022. https://doi.org/10.1016/j.actatropica.2022.106436.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.